Planned intervention: On Wednesday April 3rd 05:30 UTC Zenodo will be unavailable for up to 2-10 minutes to perform a storage cluster upgrade.
Published May 16, 2017 | Version v1
Journal article Open

Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia.

  • 1. Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Translational Alzheimer Neurobiology, Karolinska Institutet, Stockholm, Sweden.
  • 2. Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Translational Alzheimer Neurobiology, Karolinska Institutet, Stockholm, Sweden; Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden and Department of Psychology, Stockholm University, Stockholm, Sweden.
  • 3. Department of Radiology, Karolinska University Hospital Huddinge, Stockholm, Sweden.
  • 4. Department of Radiology, Karolinska University Hospital Huddinge, Stockholm, Sweden and Department of Medical Physics, Uppsala University Hospital, Uppsala, Sweden.
  • 5. Department of Radiology, Karolinska University Hospital Huddinge, Stockholm, Sweden and Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
  • 6. Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
  • 7. Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Translational Alzheimer Neurobiology, Karolinska Institutet, Stockholm, Sweden and Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden.

Description

Abstract

The development of tau-specific positron emission tomography (PET) tracers allows imaging in vivo the regional load of tau pathology in Alzheimer's disease (AD) and other tauopathies. Eighteen patients with baseline investigations enroled in a 17-month follow-up study, including 16 with AD (10 had mild cognitive impairment and a positive amyloid PET scan, that is, prodromal AD, and six had AD dementia) and two with corticobasal syndrome. All patients underwent PET scans with [18F]THK5317 (tau deposition) and [18F]FDG (glucose metabolism) at baseline and follow-up, neuropsychological assessment at baseline and follow-up and a scan with [11C]PIB (amyloid-β deposition) at baseline only. At a group level, patients with AD (prodromal or dementia) showed unchanged [18F]THK5317 retention over time, in contrast to significant decreases in [18F]FDG uptake in temporoparietal areas. The pattern of changes in [18F]THK5317 retention was heterogeneous across all patients, with qualitative differences both between the two AD groups (prodromal and dementia) and among individual patients. High [18F]THK5317 retention was significantly associated over time with low episodic memory encoding scores, while low [18F]FDG uptake was significantly associated over time with both low global cognition and episodic memory encoding scores. Both patients with corticobasal syndrome had a negative [11C]PIB scan, high [18F]THK5317 retention with a different regional distribution from that in AD, and a homogeneous pattern of increased [18F]THK5317 retention in the basal ganglia over time. These findings highlight the heterogeneous propagation of tau pathology among patients with symptomatic AD, in contrast to the homogeneous changes seen in glucose metabolism, which better tracked clinical progression.

Files

Chiotis_MolPsychiatry_2017-P12b.pdf

Files (2.9 MB)

Name Size Download all
md5:7a0a5f3bbbbb1a06e93e42fab5ce9925
2.9 MB Preview Download

Additional details

Funding

INMIND – Imaging of Neuroinflammation in Neurodegenerative Diseases 278850
European Commission